For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips will present at the NWR Virtual Health Conference to be held on Friday 1 May & Monday 4 May, 2020. Mr Phillips will provide details of recent progress in the Pharmaxis drug discovery pipeline and additional commentary on the information included in the latest Pharmaxis Quarterly Shareholder Update released earlier today, available of the company website.
Shareholders and investors are invited to participate in this free event.
Event: NWR Communications Virtual Health Conference
Presenting: Gary Phillips, CEO
Time/date: 1:40pm AEST, Friday 1 May
The event is free and investors should register in advance to view the presentation at: https://t.co/sY5jB3KKEi?amp=1Read full media release - pdf
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced that following positive results from phase 1b and long term toxicity studies, the company is now progressing to a phase 2 study of its oral anti-fibrotic pan-Lysyl Oxidase (LOX) inhibitor PXS-5505 for treatment of the rare bone cancer, myelofibrosis (MF).
- Multiple ascending dose stage of Phase 1 trial demonstrates a well-tolerated drug that effectively inhibits all enzymes in the lysyl oxidase family that are involved in fibrosis.
- Long term toxicity studies completed clearing the way for 6-month phase 2 studies in several cancers with opportunity to demonstrate disease modifying efficacy.
- Pre-clinical program, regulatory advice and opinion from leading clinicians supports progression into phase 2 study of myelofibrosis, a rare bone cancer with high unmet need and significant market opportunity.
- Pharmaxis advances its clinical stage pipeline in fibrosis that includes selective LOXL2 inhibitors (PXS-5382 and PXS-5338) for chronic fibrotic diseases like NASH and IPF, the oral pan-LOX inhibitor (PXS-5505) for acute fibrosis and cancer, and a topical pan-LOX inhibitor for scarring.